Summary of milestone payment |
Milestones |
|
Payments |
|
|
|
|
|
(1) when Company initiates a Phase I Clinical Trial of a licensed product |
|
$ |
750,000 |
|
(2) when Company initiates a Phase II Clinical Trial of a licensed product |
|
|
750,000 |
|
(3) when Company initiates a Phase III Clinical Trial of a licensed product |
|
|
1,500,000 |
|
(4) Biological License Application filing with U.S. FDA |
|
|
1,750,000 |
|
(5) First commercial sale |
|
|
1,500,000 |
|
(6) after the first $10,000,000 in net sales |
|
|
1,500,000 |
|
|
Milestones |
|
Payments |
|
|
|
|
|
(1) when Company initiates a Phase I Clinical Trial of a licensed product |
|
$ |
750,000 |
|
(2) when Company initiates a Phase II Clinical Trial of a licensed product |
|
|
750,000 |
|
(3) when Company initiates a Phase III Clinical Trial of a licensed product |
|
|
1,500,000 |
|
(4) Biological License Application filing with U.S. FDA |
|
|
1,750,000 |
|
(5) First commercial sale |
|
|
1,500,000 |
|
(6) after the first $10,000,000 in net sales |
|
|
1,500,000 |
|
|
Summary of milestone payment |
Milestones |
|
Payments |
|
|
|
|
|
|
|
|
|
1) filing of an New Drug Application (“NDA”) or regulatory approval for each licensed product |
|
$ |
750,000 |
|
(2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product |
|
|
1,750,000 |
|
|
Milestones |
|
Payments |
|
|
|
|
|
1) filing of an New Drug Application (“NDA”) or regulatory approval |
|
|
|
for each licensed product |
|
$ |
750,000 |
|
(2) upon the receipt of regulatory approval from the U.S. FDA for each |
|
|
|
|
licensed product |
|
|
1,750,000 |
|
|